Sugi Predict

Sugi Predict / Compounds / SCHEMBL1284045

SCHEMBL1284045

SCHEMBL1284045

CCOC(=O)CCCCN(C(=O)OC(C)(C)C)c1cc2nc(-c3ccc(NC)nc3)nc(N3CCOCC3)c2s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 4/20 0.51
▸ HDAC2 Q92769 4/20 0.51
▸ HDAC10 Q969S8 4/20 0.51
▸ HDAC11 Q96DB2 4/20 0.51
▸ HDAC3 O15379 3/20 0.51
▸ PIK3CA P42336 16/20 0.42
▸ PIK3CD O00329 12/20 0.42
▸ PIK3CB P42338 12/20 0.42
▸ PIK3CG P48736 11/20 0.42
▸ MTOR P42345 9/20 0.42
▸ HDAC6 Q9UBN7 3/20 0.42
▸ HDAC4 P56524 2/20 0.42
▸ HDAC7 Q8WUI4 2/20 0.42
▸ HDAC8 Q9BY41 2/20 0.42
▸ HDAC9 Q9UKV0 2/20 0.42
▸ HDAC5 Q9UQL6 2/20 0.42
▸ PIK3R1 P27986 1/20 0.42
▸ PRKDC P78527 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ NCOR2 Q9Y618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1284450 0.92 PIK3CA (0.43) HDAC1HDAC2HDAC10HDAC11HDAC3
SCHEMBL1284661 0.90 PIK3CA (0.45) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL1284413 0.90 PIK3CA (0.51) HDAC1HDAC2HDAC10HDAC11HDAC3
SCHEMBL1283922 0.89 PIK3CA (0.53) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL1284154 0.88 PIK3CA (0.53) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL1284056 0.88 PIK3CA (0.53) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL2557644 0.87 PIK3CA (0.54) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL1284928 0.83 PIK3CA (0.38) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL1284945 0.82 PIK3CA (0.38) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL1284609 0.82 PIK3CA (0.38) PIK3CAPIK3CDPIK3CBPIK3CGMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety CURIS INC (US) 2025-07-17 — — US disclosed
US-20230227467-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2023-07-20 — — US disclosed
US-11597732-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety CURIS, INC. (US) 2023-03-07 — — US disclosed
US-20220402934-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2022-12-22 — — US disclosed
US-11261195-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety CURIS, INC. (US) 2022-03-01 — — US disclosed
US-20210214370-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2021-07-15 — — US disclosed
US-10894795-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety CURIS, INC. (US) 2021-01-19 — — US disclosed
US-20200339593-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2020-10-29 — — US disclosed
US-10676482-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety CURIS, INC. (US) 2020-06-09 — — US disclosed
US-20190352310-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2019-11-21 — — US disclosed
US-10336770-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety CURIS, INC. (US) 2019-07-02 — — US disclosed
US-20170362251-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2017-12-21 — — US disclosed
US-9725461-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety CURIS, INC. (US) 2017-08-08 — — US disclosed
US-20150203509-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS INC (US) 2015-07-23 — — US disclosed
US-8906909-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety CURIS, INC. (US) 2014-12-09 — — US disclosed
US-20140155595-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS, INC. (US) 2014-06-05 — — US disclosed
US-8461157-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety CURIS, INC. (US) 2013-06-11 — — US disclosed
US-20130102595-A1 TREATMENT OF CANCERS HAVING K-RAS MUTATIONS CURIS, INC. 2013-04-25 — — US disclosed
US-20120088764-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY CURIS, INC. 2012-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155595-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-10336770-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-11261195-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-20210214370-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-11597732-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-20170362251-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-10894795-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-20120088764-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-20200339593-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-20230227467-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-20220402934-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-20150203509-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-10676482-B2 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885
US-20130102595-A1 TREATMENT OF CANCERS HAVING K-RAS MUTATIONS KRAS, HRAS, KSR2 HDAC1 6/4885HDAC2 14/4885HDAC10 21/4885
US-20190352310-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY BAZ2A, BAZ2B, PI4KB HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.